2025-02-22 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Review

**0. Key Figures & Initial Analysis:**

TDOC, Teladoc Health Inc., is a telehealth company providing virtual care services.  The company shows significant underperformance compared to the S&P 500 (VOO).

**1. Performance Comparison with S&P 500 (VOO):**

* **TDOC Cumulative Return:** -58.69%
* **VOO Cumulative Return:** 118.26%
* **Return Difference:** -176.9%  (This means TDOC underperformed VOO by 176.9 percentage points.  The relative divergence of -1.3 indicates that this underperformance is towards the lower end of the historical range of divergence between TDOC and VOO.)

The provided alpha and beta analysis shows highly volatile performance, with significant periods of both extremely high growth and substantial losses,  indicating high risk.  The beta values fluctuate considerably, suggesting substantial sensitivity to market movements (although currently low), which needs to be considered in risk management.

**Alpha & Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha | Beta | Cap(B) |
|------------|--------|--------|-------|-------|--------|
| 2015-2017  | 71.0%  | 19.3%  | 44.0% | 6.0   |       |
| 2016-2018  | 135.0% | 19.9%  | 116.0%| 8.5   |       |
| 2017-2019  | 186.0% | 19.9%  | 155.0%| 14.4  |       |
| 2018-2020  | 429.0% | 19.9%  | 401.0%| 34.4  |       |
| 2019-2021  | -14.0% | 32.1%  | -85.0%| 15.8  |       |
| 2020-2022  | -296.0%| 52.9%  | -304.0%| 4.1   |       |
| 2021-2023  | -733.0%| 52.9%  | -757.0%| 3.7   |       |
| 2022-2024  | -173.0%| 52.9%  | -206.0%| 1.6   |       |
| 2023-2025  | -38.0% | 22.9%  | -97.0%| 2.0   |       |


**2. Recent Price Movement:**

* **Closing Price:** $11.51
* **Previous Close:** $12.69
* **5-Day Moving Average:** $13.08
* **20-Day Moving Average:** $11.82
* **60-Day Moving Average:** $10.68

The price is below all three moving averages, suggesting a downward trend. The recent price drop of -9.3% is significant.


**3. Technical Indicators & Expected Return:**

* **RSI:** 56.05 (Slightly above neutral; not overly oversold)
* **PPO:** -0.40 (Negative, indicating bearish momentum)
* **20-Day Relative Divergence Change:** -0.4 (Negative, confirming short-term downward trend)
* **Expected Return:** -5845.6% (This extremely negative value is likely an error and needs clarification. A negative expected return is possible, but such a magnitude suggests a potential data issue.)


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-10-31 | -$0.19 | $0.64B        |
| 2024-08-01 | -$4.92 | $0.64B        |
| 2024-04-26 | -$0.49 | $0.65B        |
| 2023-10-27 | -$0.35 | $0.66B        |
| 2023-10-31 | -$0.35 | $0.66B        |


The earnings show consistent losses over the reported periods.  The significant drop in EPS from -$0.35 to -$4.92 in August 2024 warrants further investigation to understand the underlying cause.  Revenue remains relatively stable.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2024-09-30 | $0.64B   | 71.94%        |
| 2024-06-30 | $0.64B   | 70.73%        |
| 2024-03-31 | $0.65B   | 69.89%        |
| 2023-12-31 | $0.66B   | 70.72%        |
| 2023-09-30 | $0.66B   | 71.83%        |


**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2024-09-30 | $1.51B   | -2.21%  |
| 2024-06-30 | $1.50B   | -55.77% |
| 2024-03-31 | $2.29B   | -3.58%  |
| 2023-12-31 | $2.33B   | -1.24%  |
| 2023-09-30 | $2.29B   | -2.49%  |

Revenue is relatively stable, but profitability is concerning, given the consistently negative ROE. The significant drop in equity and ROE in Q2 2024 requires further analysis to determine the cause.


**6. Overall Analysis:**

TDOC is currently experiencing significant underperformance compared to the S&P 500.  The company shows consistent losses in earnings, despite relatively stable revenue.  Financial health is questionable given negative ROE and the significant drop in equity in Q2 2024. The recent price drop and negative technical indicators suggest a bearish trend in the short term.  The extremely negative expected return needs further investigation.  Before considering any long-term investment, a thorough analysis of the underlying reasons for the negative EPS, ROE, and overall negative performance is crucial.  The high volatility and risk associated with TDOC must also be considered.  Further investigation into the factors affecting the Q2 2024 results is critical for any investment decision.
